A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)

Long-Term Treatment, Multicenter, Open-Label Study With SPP100 in Patients With Essential Hypertension

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00246584

Enrollment

300

Registered

2005-10-31

Start date

2004-10-31

Completion date

Unknown

Last updated

2006-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, angiotensin, renin, aliskiren

Brief summary

This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)

Interventions

DRUGSPP100

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Diagnosed as essential hypertension -

Exclusion criteria

* Patients with secondary hypertension or suspected of having secondary hypertension. * Patients suspected of having malignant hypertension * Patients with any serious diseases or symptoms

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events, vital signs, abnormal laboratory changes,etc.	—

Secondary

Measure	Time frame
Change from baseline in diastolic blood pressure after 52 weeks	—
Change from baseline in systolic blood pressure after 52 weeks	—
Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 52 weeks	—

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026